Advanced Malignancies, B-Cell Lymphoma, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS, Solid Tumor
Conditions
Keywords
B-cell Lymphoma, Advanced Malignancies, Anaplastic Lymphoma Kinase (ALK), ASP3026, Solid Tumor
Brief summary
This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).
Detailed description
This study will be conducted using a traditional 3 + 3 dose escalation study design. Enrollment of at least 3 subjects is planned for each dosing cohort until the Maximum Tolerated Dose (MTD) is determined. Up to three additional subjects per cohort may be enrolled if each additional subject is known to be positive for Anaplastic Lymphoma Kinase (ALK) or Proto-Oncogene Tyrosine-Protein Kinase ROS (ROS) abnormalities. The decision to expand a cohort or dose escalate will be based on the occurrence of dose limiting toxicities (DLTs) in Cycle 1 that are considered by the Investigator to be related (possibly or probably) to ASP3026. Intra-subject dose escalation will be allowed at the discretion of the investigators. The Safety Data Review Committee may elect to enroll additional subjects in a cohort to further evaluate the dose level. Once the MTD is determined, approximately 20 additional subjects with Anaplastic Lymphoma Kinase (ALK) abnormalities will be enrolled at the Recommended Phase 2 Dose. Each cycle will include 28 days of continuous dosing with ASP3026. Treatment with ASP3026 may continue until one of the discontinuation criteria is met.
Interventions
DRUGASP3026
Tablet
Sponsors
Astellas Pharma Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Histologically or cytologically confirmed diagnosis of a relapsed/refractory solid tumor or B-cell lymphoma and meets at least 1 of the following criteria: * Disease progression despite standard therapies * No standard therapies are available or such therapies are not anticipated to result in a durable response * Standard therapies are considered unsuitable or have been refused * Able to take oral medications * Life expectancy \> 12 weeks * For the expansion cohort of the study, all subjects must be confirmed to be positive for ALK gene abnormalities * Subjects with stable brain metastasis will be allowed
Exclusion criteria
* Active central nervous system (CNS) metastases or leptomeningeal involvement as assessed through medical history review and physical examination (dose escalation subjects only) * Known history of a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) * Known hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection * Cardiac arrhythmias \> Grade 1 using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v. 4.03 * Class 3 or 4 New York Heart Association congestive heart failure, acute coronary syndrome, myocardial infarction or cerebrovascular accident within 6 months prior to Cycle 1, Day 1 * Inadequate bone marrow, renal, and/or hepatic function * Confirmed active peptic ulcer disease or history of gastrointestinal bleeding within the past 3 months * Known history of long QT syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of ASP3026 assessed by recording of adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and clinical observations | Up to 30 days after last subject discontinues treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic assessment through analysis of blood and urine samples | Up to Day 29 | — |
| Objective response rate (ORR) | 30 Days after the last subject discontinues treatment | Objective response rate is the proportion of subjects who experience complete response/remission (CR) or partial response/remission (PR) |
Countries
United States
Outcome results
None listed